questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
NADH, NADPH oxidoreductases
NADH, NADPH oxidoreductases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Molecular Docking Simulation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "NADH, NADPH oxidoreductases : Questions médicales les plus fréquentes",
"headline": "NADH, NADPH oxidoreductases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les NADH, NADPH oxidoreductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-05",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "NADH, NADPH oxidoreductases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Oxidoreductases",
"url": "https://questionsmedicales.fr/mesh/D010088",
"about": {
"@type": "MedicalCondition",
"name": "Oxidoreductases",
"code": {
"@type": "MedicalCode",
"code": "D010088",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cytochrome reductases",
"alternateName": "Cytochrome Reductases",
"url": "https://questionsmedicales.fr/mesh/D003579",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome reductases",
"code": {
"@type": "MedicalCode",
"code": "D003579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.191"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NADPH-ferrihemoprotéine reductase",
"alternateName": "NADPH-Ferrihemoprotein Reductase",
"url": "https://questionsmedicales.fr/mesh/D009251",
"about": {
"@type": "MedicalCondition",
"name": "NADPH-ferrihemoprotéine reductase",
"code": {
"@type": "MedicalCode",
"code": "D009251",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.191.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "NADH tetrazolium reductase",
"alternateName": "NADH Tetrazolium Reductase",
"url": "https://questionsmedicales.fr/mesh/D009246",
"about": {
"@type": "MedicalCondition",
"name": "NADH tetrazolium reductase",
"code": {
"@type": "MedicalCode",
"code": "D009246",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.530"
}
}
},
{
"@type": "MedicalWebPage",
"name": "NADP transhydrogenases",
"alternateName": "NADP Transhydrogenases",
"url": "https://questionsmedicales.fr/mesh/D009250",
"about": {
"@type": "MedicalCondition",
"name": "NADP transhydrogenases",
"code": {
"@type": "MedicalCode",
"code": "D009250",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.540"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NADP transhydrogenase, AB-specific",
"alternateName": "NADP Transhydrogenase, AB-Specific",
"url": "https://questionsmedicales.fr/mesh/D061087",
"about": {
"@type": "MedicalCondition",
"name": "NADP transhydrogenase, AB-specific",
"code": {
"@type": "MedicalCode",
"code": "D061087",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.540.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "NADPH dehydrogenase",
"alternateName": "NADPH Dehydrogenase",
"url": "https://questionsmedicales.fr/mesh/D009252",
"about": {
"@type": "MedicalCondition",
"name": "NADPH dehydrogenase",
"code": {
"@type": "MedicalCode",
"code": "D009252",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Quinone reductases",
"alternateName": "Quinone Reductases",
"url": "https://questionsmedicales.fr/mesh/D011808",
"about": {
"@type": "MedicalCondition",
"name": "Quinone reductases",
"code": {
"@type": "MedicalCode",
"code": "D011808",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NADPH dehydrogenase (quinone)",
"alternateName": "NAD(P)H Dehydrogenase (Quinone)",
"url": "https://questionsmedicales.fr/mesh/D016660",
"about": {
"@type": "MedicalCondition",
"name": "NADPH dehydrogenase (quinone)",
"code": {
"@type": "MedicalCode",
"code": "D016660",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.608.800.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "NADH, NADPH oxidoreductases",
"alternateName": "NADH, NADPH Oxidoreductases",
"code": {
"@type": "MedicalCode",
"code": "D009247",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Fei-Long Li",
"url": "https://questionsmedicales.fr/author/Fei-Long%20Li",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmacy, United Pharmaceutical Institute of Jiangsu University and Shandong Tianzhilvye Biotechnology Co. Ltd., Jiangsu University, Zhenjiang 212013, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Ye-Wang Zhang",
"url": "https://questionsmedicales.fr/author/Ye-Wang%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmacy, United Pharmaceutical Institute of Jiangsu University and Shandong Tianzhilvye Biotechnology Co. Ltd., Jiangsu University, Zhenjiang 212013, People's Republic of China; College of Petroleum and Chemical Engineering, Beibu Gulf University, Qinzhou 535011, People's Republic of China. Electronic address: zhangyewang@ujs.edu.cn."
}
},
{
"@type": "Person",
"name": "Chuanwu Xia",
"url": "https://questionsmedicales.fr/author/Chuanwu%20Xia",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 53226, USA."
}
},
{
"@type": "Person",
"name": "Anna L Shen",
"url": "https://questionsmedicales.fr/author/Anna%20L%20Shen",
"affiliation": {
"@type": "Organization",
"name": "McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53706, USA."
}
},
{
"@type": "Person",
"name": "Jung-Ja P Kim",
"url": "https://questionsmedicales.fr/author/Jung-Ja%20P%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 53226, USA. Electronic address: jjkim@mcw.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors.",
"datePublished": "2022-08-26",
"url": "https://questionsmedicales.fr/article/36026508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0268269"
}
},
{
"@type": "ScholarlyArticle",
"name": "Py-CoMFA, docking, and molecular dynamics simulations of Leishmania (L.) amazonensis arginase inhibitors.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38773273",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-62520-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exploring the molecular mechanism of ginseng against anthracycline-induced cardiotoxicity based on network pharmacology, molecular docking and molecular dynamics simulation.",
"datePublished": "2024-09-06",
"url": "https://questionsmedicales.fr/article/39243097",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s41065-024-00334-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study of the antidiabetic mechanism of berberine compound on FOXO1 transcription factor through molecular docking and molecular dynamics simulations.",
"datePublished": "2024-07-09",
"url": "https://questionsmedicales.fr/article/38981921",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00894-024-06060-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Research advances of molecular docking and molecular dynamic simulation in recognizing interaction between muscle proteins and exogenous additives.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37453331",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.foodchem.2023.136836"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "NADH, NADPH oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D009247"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : NADH, NADPH oxidoreductases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur NADH, NADPH oxidoreductases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur NADH, NADPH oxidoreductases",
"description": "Comment diagnostiquer une déficience en NADH oxydoréductases ?\nQuels tests sanguins sont utiles pour évaluer NADPH ?\nQuels symptômes indiquent un problème avec ces enzymes ?\nLes tests d'activité enzymatique sont-ils fiables ?\nPeut-on détecter des anomalies génétiques liées à ces enzymes ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Molecular+Docking+Simulation&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur NADH, NADPH oxidoreductases",
"description": "Quels sont les symptômes d'une carence en NADH ?\nComment se manifeste une déficience en NADPH ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes varient-ils selon l'âge ?\nDes symptômes digestifs peuvent-ils apparaître ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Molecular+Docking+Simulation&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur NADH, NADPH oxidoreductases",
"description": "Comment prévenir les déficiences en NADH ?\nY a-t-il des habitudes de vie à adopter ?\nLes bilans de santé réguliers sont-ils utiles ?\nLes vaccinations peuvent-elles jouer un rôle ?\nL'éducation nutritionnelle est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Molecular+Docking+Simulation&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur NADH, NADPH oxidoreductases",
"description": "Quels traitements existent pour les déficiences enzymatiques ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à réguler ces enzymes ?\nY a-t-il des traitements naturels recommandés ?\nLes transfusions sanguines sont-elles nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Molecular+Docking+Simulation&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur NADH, NADPH oxidoreductases",
"description": "Quelles complications peuvent survenir avec une déficience en NADH ?\nLes infections sont-elles une complication fréquente ?\nY a-t-il des risques de maladies chroniques ?\nLes complications cardiovasculaires sont-elles possibles ?\nDes complications hématologiques peuvent-elles survenir ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Molecular+Docking+Simulation&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur NADH, NADPH oxidoreductases",
"description": "Quels facteurs de risque sont associés aux déficiences enzymatiques ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes maladies génétiques sont-elles un facteur ?\nLe stress oxydatif joue-t-il un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D009247?mesh_terms=Molecular+Docking+Simulation&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en NADH oxydoréductases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses génétiques peuvent être utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles pour évaluer NADPH ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dosages de NADPH et d'autres coenzymes dans le sang peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec ces enzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, faiblesse musculaire et troubles métaboliques peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Les tests d'activité enzymatique sont-ils fiables ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent utilisés pour évaluer la fonction des NADH et NADPH oxydoréductases."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies génétiques liées à ces enzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent identifier des mutations affectant ces enzymes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en NADH ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, troubles cognitifs et faiblesse musculaire."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une déficience en NADPH ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des infections fréquentes et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en cas de dysfonctionnement enzymatique."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'âge et de l'état de santé général."
}
},
{
"@type": "Question",
"name": "Des symptômes digestifs peuvent-ils apparaître ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles digestifs peuvent être liés à des anomalies dans le métabolisme énergétique."
}
},
{
"@type": "Question",
"name": "Comment prévenir les déficiences en NADH ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en nutriments essentiels peut aider à prévenir ces déficiences."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à adopter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain incluant exercice et gestion du stress est recommandé."
}
},
{
"@type": "Question",
"name": "Les bilans de santé réguliers sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans réguliers peuvent aider à détecter précocement des anomalies enzymatiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles jouer un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui aggravent les déficiences."
}
},
{
"@type": "Question",
"name": "L'éducation nutritionnelle est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre l'importance des nutriments peut aider à prévenir les carences."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les déficiences enzymatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des suppléments enzymatiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique est explorée pour traiter certaines déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à réguler ces enzymes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent aider à moduler l'activité des NADH et NADPH oxydoréductases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels recommandés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antioxydants et des nutriments peuvent soutenir la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles nécessaires ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas graves, des transfusions peuvent être nécessaires pour corriger des déficiences."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en NADH ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des déficiences enzymatiques sont plus susceptibles aux infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies chroniques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déficiences peuvent augmenter le risque de maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Les complications cardiovasculaires sont-elles possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles métaboliques peuvent entraîner des complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Des complications hématologiques peuvent-elles survenir ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans le métabolisme peuvent entraîner des complications hématologiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux déficiences enzymatiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies métaboliques et une mauvaise nutrition."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences peuvent être plus fréquentes chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques sont-elles un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques prédisposent aux déficiences en NADH et NADPH."
}
},
{
"@type": "Question",
"name": "Le stress oxydatif joue-t-il un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut aggraver les déficiences enzymatiques et leurs effets."
}
}
]
}
]
}
Antimalarial drug resistance has thrown a spanner in the works of malaria elimination. New drugs are required for ancillary support of existing malaria control efforts. Plasmodium falciparum requires ...
Leishmaniasis is a disease caused by a protozoan of the genus Leishmania, affecting millions of people, mainly in tropical countries, due to poor social conditions and low economic development. First-...
Previous clinical and basic studies have revealed that ginseng might have cardioprotective properties against anthracycline-induced cardiotoxicity (AIC). However, the underlying mechanism of ginseng a...
Fourteen drug-disease common targets were identified. Enrichment analysis showed that the AGE-RAGE in diabetic complications, fluid shear stress and atherosclerosis, and TNF signaling pathway were pot...
This study suggested that ginseng might exert their protective effects against AIC through the derived effector compounds beta-Sitosterol, Kaempferol and Fumarine by targeting CCNA2, STAT1, and ICAM1,...
Diabetes mellitus (DM) is a metabolic disorder disease that causes hyperglycemia conditions and associated with various chronic complications leading to mortality. Due to high toxicity of conventional...
Docking between ligand and FOXO1 receptor was carried out with Autodock4.2. For molecular dynamics simulations, the force fields of DNA.OL15, protein.ff14SB, gaff2, and tip3p were used....
During storage and processing, muscle proteins, e.g. myosin and myoglobin, will inevitably undergo degeneration, which is thus accompanied by quality deterioration of muscle foods. Some exogenous addi...
Cereblon (CRBN) is a substrate receptor of E3 ubiquitin ligase as well as the target of thalidomide and lenalidomide, plays a vital role in endogenous protein degradation. In this article, two series ...
Direct oral anticoagulants are an important and relatively new class of synthetic anticoagulant drugs commonly used for the pharmacotherapy of thromboembolic disorders. However, they still have some l...
Cancer is a serious threat to human life and social development and the use of scientific methods for cancer prevention and control is necessary. In this study, HQSAR, CoMFA, CoMSIA and TopomerCoMFA m...
The pandemic of COVID-19 caused by SARS-CoV-2 has made a worldwide health emergency. Despite the fact that current vaccines are readily available, several SARSCoV-2 variants affecting the existing vac...
Oritavancin is a semi-synthetic lipoglycopeptide antibiotic primarily used to treat serious infections caused by Gram-positive bacteria. The aim of this study was to elucidate possible molecular targe...
Computational methods were used in this study which include target prediction, molecular docking, molecular dynamics simulation, pharmacokinetics prediction, and physiological-based pharmacokinetics (...
Oritavancin was moderately soluble in water and did not permeate the blood-brain barrier. Seven molecular targets were identified in humans. Molecular docking results showed highest binding affinity o...
This comprehensive computational study has provided invaluable insights into the pharmacological profile of Oritavancin, aiding its further development and optimization for clinical use....